Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.
about
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World PerspectiveConsensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?Immunoprophylaxis of respiratory syncytial virus: global experience.Palivizumab in the prevention of respiratory syncytial virus disease.Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.Palivizumab for preterm infants. Is it worth it?Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.Palivizumab in the prophylaxis of respiratory syncytial virus infection.Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSVPalivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Prophylaxis of respiratory syncytial virus in Canada in 2003.Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.A 4-year survey on palivizumab respiratory syncytial virus (RSV)-prophylaxis: how can compliance be improved?Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.Adherence and outcomes: a systematic review of palivizumab utilization.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Current respiratory syncytial virus prevention strategies in high-risk infants.Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).Effectiveness of palivizumab prophylaxis in infants and children in Florida
P2860
Q26830864-FD2F54EA-DF2B-406E-9DAF-D8108FB5931CQ30245434-DCB1C7EC-C61B-4A59-AB7C-0BBDDED9E738Q33610003-980EA0C6-8F97-4608-A1FE-B3DC6A825E93Q33705088-04E7117E-08A1-45CA-9C4B-A64DA6F59C22Q33999369-05546A0D-66E3-4541-BB6F-0E6A1F7CC7D6Q34430473-CAF75DC4-45BC-4C5F-97FB-86C54A04ED44Q34740842-5DDE82B2-2728-4031-9321-CD90150D47FCQ34974757-E11AB966-8E68-4749-A720-ACCFB0599755Q34986049-F27C71DD-2B28-4684-9CD5-EFC3E94DDFA8Q35296973-5E631602-BF62-400B-A8AA-375FDC13AD27Q35778606-211AD0A0-FA9F-4D32-8D82-3D106F2A7AFEQ35980935-50169EDA-1F33-43FD-830D-2AEB95708045Q36278040-E07DAB26-A131-4EB9-AD5D-2F8392CDF3C7Q36922280-2AAE1009-EF41-4E8C-A36D-43CB67DBB86BQ37252918-C255B9FE-33A8-4E25-B0F2-31C68B973CA5Q37290618-9C627880-A565-493F-BA25-3BC021A2D684Q37481321-F8CA023A-9A8F-4D5D-AD02-5AA12F0C4A57Q38830272-A6B38321-5EE9-4292-82B6-D0C54887179EQ39262123-78B6ACF2-8709-42E8-9108-2A25C6A42504Q42262149-E638E65B-3D5C-4A4E-BD6A-E5B60D2C935DQ44480572-DF14E25A-EF61-4496-901B-F901E7FD122CQ45375474-96CEA731-45E6-4E2F-8163-BB2F102A5D54Q45396238-CA59C5AD-34C5-4839-B620-3CC712D02813Q45414326-EC5BA633-D10E-434F-9CC6-BEC5916D60FEQ45731138-ACB731DA-5E1A-4BF5-967F-12E1E55B1366Q45731142-B00718C3-F329-45D1-AC62-9DCB7C1F7E1AQ47582466-E932F352-7BE3-4840-BE7C-218A24BEEA9FQ50262223-4A2DFD84-7C73-4797-B0FE-3D85F8A19870Q51704334-4D387FF1-201A-4048-9A28-CFAC95149944Q51718949-205EC3A9-D42A-42F2-9964-EEBC04BFBFC8Q57830092-16C95A1B-D542-49CC-A09A-25C6F2B689F8
P2860
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@ast
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@en
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@nl
type
label
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@ast
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@en
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@nl
prefLabel
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@ast
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@en
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@nl
P1476
Effectiveness of palivizumab: ...... ivizumab Outcomes Study Group.
@en
P2093
Sorrentino M
P304
P356
10.1097/00006454-200011000-00007
P577
2000-11-01T00:00:00Z